Swiss pharma firm Sandoz invests $440 million in Slovenia
Select your language
Generated with artificial intelligence.
Listening:
Swiss pharma firm Sandoz invests $440 million in Slovenia
Sandoz is expanding its presence in Slovenia. The Basel-based generics giant has launched the construction of a new biosimilars production centre in Brnik at a cost of $440 million (CHF349 million).
+Get the most important news from Switzerland in your inbox
The announcement brings current and planned investments in the small Alpine country to more than $1.1 billion by 2029, according to a press release issued on Tuesday by the specialist in generic and biosimilar treatments. These include a new biosimilars production centre in Lendava and a development centre in the capital, Ljubljana.
Sandoz intends to take advantage of an “unprecedented market opportunity”, with patent expiries expected to reach $222 billion over the next ten years. The Group believes it is the leading foreign direct investor in the European country.
More
Swiss pharma’s big bet on Slovenia
Translated from German by DeepL/jdp
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.